UCB SA (OTCMKTS:UCBJF – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $184.00 and last traded at $184.00, with a volume of 0 shares. The stock had previously closed at $184.00.
UCB Price Performance
The stock has a fifty day moving average of $179.47 and a 200 day moving average of $153.52. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- Conference Calls and Individual Investors
- Battle of the Retailers: Who Comes Out on Top?
- Investing in Construction Stocks
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
